Private company

PARDES BIOSCIENCES, INC.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a clinical-stage biopharmaceutical company that is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases and on preventing the next pandemic, starting with our lead candidate, pomotrelvir (formerly known as PBI-0451), which targets the current coronavirus disease (coronavirus disease 2019 or COVID-19).”50 It is headquartered in Carlsbad, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersCarlsbad, California1
  • Incorporated inDE2
  • Business address2173 Salk Avenue, Suite 250, Pmb#052, Carlsbad, Ca 920082
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-53.6%Return on equity3

Financial statements

Revenue43$0 in 2022
02021: $0$020212022: $0$02022
Net income3-$96.6M in 2022+151% since 2021
-$100.0M-$75.0M-$50.0M-$25.0M02021: -$38.5M-$38.5M20212022: -$96.6M-$96.6M2022+151%
Fiscal year202020212022
Revenue$04$03
Research and development$28.2M3$70.3M3
Operating expenses$38.5M3$99.8M3
Operating income$38.5M4
Income tax$03$03
Net income-$38.5M3-$96.6M3
Earnings per share-$10.133-$1.663
Earnings per share (diluted)-$10.133-$1.663
Shares (weighted, basic)3.8M shares358.1M shares3
Shares (weighted, diluted)3.8M shares358.1M shares3

Compare PARDES BIOSCIENCES, INC. with another company

Corporate structure

PARDES BIOSCIENCES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PARDES BIOSCIENCES, INC.

  • FS Development Holdings II, LLC Filed SC 13D/A on PARDES BIOSCIENCES, INC., latest Aug 31, 2023 (6 filings since Dec 30, 2021)
  • Beryl Capital Management LLC Filed SC 13G on PARDES BIOSCIENCES, INC., latest Aug 14, 2023
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on PARDES BIOSCIENCES, INC., latest Feb 14, 2023 (3 filings since Dec 13, 2021)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on PARDES BIOSCIENCES, INC., latest Feb 14, 2023 (2 filings since Jan 10, 2022)
  • BML Investment Partners, L.P. Filed SC 13G/A on PARDES BIOSCIENCES, INC., latest Feb 8, 2023 (2 filings since Dec 30, 2022)
  • Lynx1 Capital Management LP Filed SC 13G on PARDES BIOSCIENCES, INC., latest Jan 23, 2023
  • VK Services, LLC Filed SC 13G on PARDES BIOSCIENCES, INC., latest Feb 14, 2022
  • Uri A. Lopatin Filed SC 13D on PARDES BIOSCIENCES, INC., latest Feb 7, 2022
  • Frazier Life Sciences Public Fund, L.P. Filed SC 13G/A on PARDES BIOSCIENCES, INC., latest Jan 28, 2022 (2 filings since Dec 17, 2021)
  • PARDES BIOSCIENCES, INC. Carlsbad, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PARDES BIOSCIENCES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$59.3M3 Dec 31, 2022$268.7M3 Dec 31, 2021−77.9%
Marketable securities, current$138.1M3 Dec 31, 2022$03 Dec 31, 2021

Leadership

Who has led PARDES BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Uri A. Lopatin2021–2022
  2. Thomas G. Wiggans2022–2023

President

  1. Uri A. Lopatin2021–2022

Chief financial officer

  1. Dennis D. Ryan2021
  2. Heidi Henson2021–2023
2025
Board members and other officers (18)

Former names

  • FS Development Corp. IISep 2, 2020 to Dec 23, 20212

Timeline

  1. Aug 31, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights27
  2. Jul 17, 20238-K Entered a material agreement; Executive or director change; Regulation FD disclosure28
  3. Jun 5, 20238-K Executive or director change; Shareholder vote29
  4. May 18, 20238-K Executive or director change30
  5. May 5, 20238-K Results of operations31
  6. Apr 21, 20238-K Executive or director change32
  7. Apr 3, 20238-K Results of operations; Exit or restructuring costs; Regulation FD disclosure33
  8. Mar 14, 20238-K Results of operations34
  9. Nov 7, 20228-K Results of operations35
  10. Oct 17, 20228-K Executive or director change36
  11. Sep 14, 20228-K Executive or director change; Regulation FD disclosure37
  12. Sep 13, 20228-K Other events38
  13. Mar 4, 2022New chief executive Thomas G. Wiggans becomes CEO7
  14. Dec 27, 2021New chief executive Uri A. Lopatin becomes CEO8

Calendar

When it reported results

  1. May 5, 2023Reported quarterly or annual results31
  2. Apr 3, 2023Reported quarterly or annual results33
  3. Mar 14, 2023Reported quarterly or annual results34
  4. Nov 7, 2022Reported quarterly or annual results35
  5. Aug 15, 2022Reported quarterly or annual results39
  6. May 10, 2022Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

225 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 33 major events, 86 insider forms, 19 large holders, 78 other. The latest 20:

  1. Sep 18, 2023CT ORDER EDGAR
  2. Sep 11, 202315-12G EDGAR
  3. Aug 31, 2023EFFECT EDGAR
  4. Aug 31, 2023EFFECT EDGAR
  5. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  6. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  7. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  8. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  9. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  10. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  11. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  12. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  13. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  14. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  15. Aug 31, 20234 FORM 4 SUBMISSION EDGAR
  16. Aug 31, 2023SC 13E3/A EDGAR
  17. Aug 31, 2023SC 14D9/A EDGAR
  18. Aug 31, 20234 EDGAR
  19. Aug 31, 2023SC 13D/A EDGAR
  20. Aug 31, 2023S-8 POS EDGAR

The 225 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 5, 2023Foresite Capital Opportunity Management V, LLC10% ownerBuy773,952$1.50$1.2MForm 4
Apr 5, 2023Tananbaum James B.President and CEOBuy773,952$1.50$1.2MForm 4
Dec 8, 2022Brusky Sean P.Chief Commercial OfficerBuy21,000$1.19$25.0KForm 4
Dec 5, 2022WIGGANS THOMAS GChief Executive OfficerBuy12,500$1.09$13.6KForm 4
Dec 2, 2022WIGGANS THOMAS GChief Executive OfficerBuy12,500$1.07$13.4KForm 4
Dec 1, 2022Tananbaum James B.President and CEOBuy637,420$0.85$541.8KForm 4
Dec 1, 2022WIGGANS THOMAS GChief Executive OfficerBuy25,000$1.04$26.0KForm 4
Dec 22, 2021Foresite Capital Opportunity Management V, LLC10% ownerBuy325,000$10.00$3.2MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How PARDES BIOSCIENCES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPARDES BIOSCIENCES, INC.1
  • CIK0001822711
  • Employer ID (EIN)85-26963061
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address2173 Salk Avenue, Suite 250, Pmb#052, Carlsbad, CA 920081
  • Phone415-649-87581
  • Shares outstanding62,011,756 as of Aug 1, 20235
  • Public float$114.5M as of Jun 30, 20223
  • On EDGAR sinceSep 2, 20201
  • Filings262 in all: 4 (66), 8-K (36), 3 (24), 425 (17), 424B3 (14), UPLOAD (9), 10-Q (8), CORRESP (8)1
    All 43 form types

    EFFECT (8), SC 13G (7), 4/A (6), SC 13D/A (5), SC 13E3/A (5), SC 13G/A (5), POS AM (4), S-4/A (4), SC 14D9/A (3), 10-K (2), DEF 14A (2), DEFA14A (2), S-1 (2), S-1/A (2), SC 13D (2), SC 13E3 (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), ARS (1), CERT (1), CT ORDER (1), DRS (1), S-1MEF (1), S-3 (1), S-4 (1), S-8 (1), S-8 POS (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 14, 2023
    Quarterly report (10-Q) Aug 4, 2023
    Proxy statement (DEF 14A) Apr 20, 2023
    Latest 8-K (8-K) Aug 31, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50